Literature DB >> 6357074

Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora.

B Kemmerich, H Warns, H Lode, K Borner, P Koeppe, H Knothe.   

Abstract

Eight healthy volunteers each received 2.0 g of ceftazidime by constant intravenous infusion over 20 min twice daily every 12 h for 8 days. Concentrations of ceftazidime in serum and urine were measured by a microbiological assay and by high-pressure liquid chromatography. Qualitative and quantitative studies on aerobic and anaerobic fecal flora were carried out before, during, and 2 weeks after the end of treatment. The mean (+/- standard deviation) maximum drug concentration in serum at the end of the 20-min infusion (day 1) was 185.5 +/- 28.5 micrograms/ml, decreasing to 0.8 +/- 0.4 microgram/ml after 12 h. The mean recovery of drug in urine at 12 h was 71.5 +/- 12.2%. Pharmacokinetic parameters calculated on the basis of a two-compartment model were as follows: elimination half-life, 110.5 +/- 15.2 min; volume of distribution at steady state, 21.2 +/- 2.6 liters/100 kg; volume of distribution by the area method, 26.2 +/- 4.0 liters/100 kg; area under the serum concentration-time curve, 293.3 +/- 47.8 micrograms X h/ml; total body clearance, 116.4 +/- 20.3 ml/min per 70 kg; renal clearance, 82.2 +/- 15.1 ml/min per 70 kg. The agar diffusion test and high-pressure liquid chromatographic analysis showed a good correlation of results. Metabolites of ceftazidime could not be detected by high-pressure liquid chromatography in serum or urine. No accumulation of ceftazidime could be observed during the 8-day study period. Mean maximum drug levels in serum were 185.5 to 214.5 micrograms/ml, and mean trough levels were 0.8 to 1.1 micrograms/ml (days 1 to 8). No severe side effects were noted. During ceftazidime treatment, anaerobes were left intact, whereas members of the family Enterobacteriaceae could be isolated from stool in only three of eight subjects. Two weeks after discontinuation of the drug, all stool specimens contained ampicillin- and cefazolin-resistant gram-negative rods.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357074      PMCID: PMC185321          DOI: 10.1128/AAC.24.3.333

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

2.  [Intestinal flora and antibiotics with special reference to tetracycline].

Authors:  H KNOTHE
Journal:  Dtsch Med Wochenschr       Date:  1963-07-26       Impact factor: 0.628

3.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

4.  [The action of ampicillin on the intestinal flora in healthy subjects].

Authors:  H Knothe; B Wiedemann
Journal:  Zentralbl Bakteriol Orig       Date:  1965-08

Review 5.  The tetracyclines: prospects at the beginning of the 1980s.

Authors:  I Chopra; T G Howe; A H Linton; K B Linton; M H Richmond; D C Speller
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

6.  A program for non-linear regression analysis to be used on desk-top computers.

Authors:  P Koeppe; C Hamann
Journal:  Comput Programs Biomed       Date:  1980-12

7.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

8.  Changes in gut flora after cephalexin treatment.

Authors:  H Gaya; P I Adnitt; P Turner
Journal:  Br Med J       Date:  1970-09-12
  8 in total
  22 in total

1.  Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Authors:  R H Barbhaiya; S T Forgue; C R Gleason; C A Knupp; K A Pittman; D J Weidler; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  The non-enzymatic inactivation of thirteen beta-lactam antibiotics in human faeces.

Authors:  G Jansen; F Weissing; H de Vries-Hospers; R Tonk; D van der Waaij
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

3.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.

Authors:  M Boeckh; H Lode; K Borner; G Höffken; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

5.  High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Authors:  R H Barbhaiya; S T Forgue; W C Shyu; E A Papp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

6.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

7.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

9.  Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.

Authors:  D Höffler; P Koeppe; M Corcilius; A Przyklinik
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

10.  Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.

Authors:  W Paulfeuerborn; H J Müller; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.